RxDoctor Payments Data

Victoria Specian

Physician Assistant · Shreveport, LANPI 1720132012

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 308 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Alkermes, Inc. at 24.3% of the total. 2025 is the largest year on record at $2,110, 2.1 times the $993 reported in 2021. Among physician assistant clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,052in general payments, 2019–2025

Across 308 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • AbbVie$815
  • Teva Pharmaceuticals USA, Inc.$694
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$608
  • Vanda Pharmaceuticals Inc.$584
  • Otsuka America Pharmaceutical, Inc.$489
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$5,99099%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,052 in reported general payments places this provider in the 95th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$43,284
Desvenlafaxine Succinate ErDesvenlafaxine Succinate23$706
Venlafaxine Hcl ErVenlafaxine Hcl18$232
Escitalopram Oxalate15$67
Amitriptyline Hcl15$64
Buspirone Hcl12$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$293$43,28413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →